Clinical Trials Browser

Phase 2 × Leukemia × Nivolumab × Clear all

NCT02530463 2026-03-05

Nivolumab and/or Ipilimumab With or Without Azacitidine in Treating Patients With Myelodysplastic Syndrome

Phase 2 Active not recruiting

MyeloidOther hematologic neoplasm

Leukemia, Myelodysplastic Syndromes

NCT02599649 2020-01-14

Lirilumab and Nivolumab With 5-Azacitidine in Patients With Myelodysplastic Syndromes (MDS)

Phase 2 Terminated

10 enrolled 8 charts

MyeloidOther hematologic neoplasm

Leukemia, Myelodysplastic Syndromes